Gilenya® shows positive clinical outcomes in new trial

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Gilenya® shows positive clinical outcomes in new trial

Postby MSUK » Thu Dec 15, 2011 1:41 am

Image


Novartis announced today new data from the Phase III 2309 study showing patients with relapsing-remitting multiple sclerosis (RRMS) treated with Gilenya® (fingolimod) had a statistically significant 48% reduction in annualized relapse rates (ARR) at 24 months compared to placebo. Study 2309 is the third Phase III clinical trial to demonstrate a significant reduction of relapse rates with Gilenya treatment in patients with RRMS.

The two previous Gilenya studies involved a two-year, placebo-controlled trial and a one-year, head-to-head trial against interferon-beta-1a (IM) in which the once-daily oral medicine showed a 54% and a 52% relative reduction in ARR, respectively... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2120
Joined: Wed Oct 14, 2009 3:00 pm

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service